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ABSTRACT
Low-grade gliomas (LGG) encompass a heterogeneous group of tumors that are 
clinically, histologically and molecularly diverse. Treatment decisions for patients 
with LGG are directed toward improving upon the natural history while limiting 
treatment-associated toxiceffects. Recent evidence has documented a utility for 
adjuvant chemotherapy with procarbazine, CCNU (lomustine), and vincristine (PCV) 
or temozolomide (TMZ). We sought to determine the comparative utility of PCV and 
TMZ for patients with LGG, particularly in context of molecular subtype. A literature 
search of PubMed was conducted to identify studies reporting patient response to PCV, 
TMZ, or a combination of chemotherapy and radiation therapy (RT). Eligibility criteria 
included patients 16 years of age and older, notation of LGG subtype, and report of 
progression-free survival (PFS), overall survival (OS), and treatment course. Level 
I, II, and III data were included. Adjuvant therapy with PCV resulted in prolonged 
PFS and OS in patients with newly diagnosed high-risk LGG. This benefit was accrued 
most significantly by patients with tumors harboring 1p/19q codeletion and IDH1 
mutation. Adjuvant therapy with temozolomide was associated with lower toxicity 
than therapy with PCV. In patients with LGG with an unfavorable natural history, 
such as with intact 1p/19q and wild-type IDH1, RT/TMZ plus adjuvant TMZ may be 
the best option. Patients with biologically favorable high-risk LGG are likely to derive 
the most benefit from RT and adjuvant PCV.
INTRODUCTION
Low-grade gliomas (LGG) comprise a small portion 
of all primary brain tumors, roughly 5 to 10%. These 
tumors typically arise in younger adults, between 25 and 
45 years of age, whereas anaplastic and high-grade tumors 
are more common in older patients. The natural history of 
most cases of low-grade gliomas is relatively favorable; 
examination of untreated patients followed by serial MRI 
revealed an annual growth rate of 4 to 6 mm per year [1]. 
Previous studies had delineated features of increased risk 
and poorer natural history, including age over 40 years, 
astrocytic histology, tumor diameter 6cm or longer, tumor 
crossing the midline, and neurological deficit prior to 
surgery. These features define a group that we will refer to 
as high-risk LGG [2].
Previous convention differentiated diffuse 
grade II and III gliomas into two basic subtypes: 
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oligodendroglioma and astrocytoma. A third hybrid 
category, oligoastrocytoma, was used for tumors 
showcasing both oligodendroglioma and astrocytoma 
characteristics. Over the last five years, our understanding 
of LGG has evolved significantly, with a shift from 
classification of these tumors based on histology towards 
stratification of risk based on molecular subtype [3, 4]. 
According to the 2016 WHO classification system, grade 
II oligodendroglioma is now defined by an isocitrate 
dehydrogenase (IDH) mutation with whole-arm codeletion 
of chromosomal arms 1p and 19q, whereas IDH mutation 
combined with intact 1p and 19q chromosomal status is 
classified as IDH-mutant astrocytoma. Histological LGG 
in the setting of wild-type IDH is distinguished from IDH-
mutant LGG and described as harboring a particularly 
poor natural history. While histological grade continues 
to be a factor in treatment consideration, the prognoses 
of patients with these tumors has been shown to correlate 
more closely with molecular alterations than with grade 
[3, 5, 6].
Treatment of patients with high-risk LGG is 
directed toward improving on the natural history 
of the disease, that is, extending time to malignant 
transformation and overall survival, while limiting 
treatment-associated morbidities and neurologic 
disability. Recent evidence has documented a utility 
for adjuvant chemotherapy with procarbazine, CCNU 
(lomustine), and vincristine (PCV) or temozolomide 
(TMZ) in the management of LGG. Unfortunately, most 
of these studies predate contemporary stratification 
systems for LGG, and conclusions of published series of 
glioma need to be re-examined in the light of the shifts 
that are brought about by the new WHO classification. 
We sought to determine the comparative utility of PCV 
and TMZ for patients with LGG, particularly in the 
context of molecular subtype. This review summarizes 
published data on adjuvant chemotherapy with PCV or 
TMZ for patients with LGG.
RESULTS
Our search of the PubMed database yielded a total 
of 1,209 papers, of which 19 studies met the inclusion 
and exclusion criteria: two randomized control trials, 
thirteen cohort studies, and five retrospective studies 
(Supplementary Figure 1) [7]. From these studies, 1,720 
adult patients were accrued for the systematic review. 
Table 1 and Table 2 summarize the key findings and 
survival data for the included studies utilizing PCV and 
TMZ, respectively. Figure 1, Figure 2, and Figure 3 
display superimposed Kaplan-Meier curves from included 
studies relating OS and PFS to treatment and molecular 
subtype. Of these 19 papers, ten examined PCV or TMZ 
as a salvage agent at progression following RT, and were 
excluded from analysis.
Evidence for use of PCV in patients with LGG
We identified five studies in which survival 
outcomes for patients with LGG treated with PCV were 
reported (Table 1) [8–12]. These studies included 365 
patients with a median age of 43.5 years (age range: 36.0-
46.5). Of these, four reported survival data meeting our 
designated requirements for analysis, resulting in a cohort 
of 344 patients for study with a median age of 43.75 
years (age range 36.0-46.5) [8–10, 12]. Taal et al. (2015) 
reported a median OS of 120 months when using PCV 
alone [12]. Buckner et al. (2016) reported a median PFS 
and OS of 48 and 94 months when RT was administered 
alone, respectively [9]. The median PFS for PCV alone 
was 32.5 months (PFS range: 19.0-46.0) [10, 12]. PFS 
when administering PCV in combination with RT was 
124.8 median months [9]. Only one study reported 5-year 
PFS within this context, with 44% and 61% PFS for RT 
and a combination of RT and PCV, respectively [9].
Evidence for use of PCV in patients with 
histologically subtyped LGG
None of the trials identified in our study reported 
histologic subtype and OS or PFS following treatment 
with PCV.
Evidence for use of PCV in patients with 
molecular-subtyped LGG
Taal and colleagues reported a median PFS and OS 
of 35 months and 83 months, respectively, for patients 
with intact 1p/19q [12]. Median PFS for patients with 
1p/19q codeletion was 67 months; median OS was not 
reached for patients in this cohort.
Buckner and colleagues treated patients with newly 
diagnosed high-risk LGG with PCV after radiation 
therapy at the time of initial diagnosis [9]. IDH1 R132H 
mutations were detected in 35 of 57 patients (61%) in 
the group that received radiation therapy alone and in 36 
of 56 (64%) in the group that received radiation therapy 
plus chemotherapy. In this cohort, 78% of patients 
were diagnosed with oligodendroglioma, 54% with 
oligoastrocytoma, and 48% with astrocytoma. OS was 
reported as 61.2 and 157.2 median months for patients 
with wild-type and mutant IDH1, respectively.
Adverse events for patients with LGG treated 
with PCV
Completion of therapy was an issue in the study 
of Taal et al., in which only sixteen patients (50%) 
completed six cycles [12]. Toxicities encountered in all 
studies included bone marrow toxicity, diarrhea, fatigue, 
and hepatotoxicity. Grade III and IV toxicities were 
encountered in 47% and 3% of patients, respectively. In 
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the study of Lebrun and colleagues, 9.1% of 33 patients 
developed a grade III or IV hematological toxicity [10]. 
Buckner and colleagues (2003) reported grade III/IV 
leukopenia and thrombocytopenia in 75% and 64% of 
patients, respectively [8]. Buckner reported grade III and 
grade IV blood or bone marrow toxicity in 41.6% and 
9.6% of 125 patients, respectively [8]. In contrast, patients 
in the radiation-alone treatment group had 0.8% and 0% 
grade III and IV blood or bone marrow toxicity.
Evidence for use of TMZ with LGG
Fourteen studies assessing survival outcomes with 
TMZ met our criteria for inclusion (Table 2) [13–26]. These 
studies included 1,355 patients with a median age of 41 years 
(age range: 38-49). Of these, six studies reported survival 
data meeting our designated requirements for analysis, 
which resulting in a cohort of 933 patients for study with 
a median age of 41.5 years (age range 38-49) [13, 15, 17, 
21, 25, 26]. A median OS of 116.4 months was found when 
administering TMZ on its own [26]. A median 5-year OS 
of 57.1% was reported when combining TMZ and RT [15].
An open-label, phase 3 European and Canadian 
intergroup study randomized adult patients with LGG 
and at least one high-risk feature to either conformal 
radiotherapy (up to 50.4 Gy) or dose-dense oral TMZ 
(for a maximum of 12 cycles). The median PFS for RT 
alone was 46 months, while median PFS for TMZ alone 
was 31.0 months (PFS range: 21.8-45.6) [13, 17, 21, 25, 
26]. One study reported median PFS of 54 months when 
administering TMZ in combination with RT [15]. Five-
year PFS was found to be 40.18% when using RT alone 
[13]. Median 5-year PFS for TMZ alone was 28.92% [13].
Evidence for use of TMZ in patients with 
histologically subtyped LGG
Only one study reporting on the use of TMZ 
in patients with LGG included data on histological 
subtype. Wahl et al reported an OS of 129.6, 85.2, 
and 68.4 median months for oligodendrogliomas, 
astrocytomas, and oligoastrocytomas, respectively 
[26]. The median PFS was 55.2, 39.6, and 32.4 
months, for oligodendrogliomas, astrocytomas, and 
oligoastrocytomas, respectively [26].
Evidence for use of TMZ in patients with 
molecular-subtyped LGG
Only one study reporting on the use of TMZ in 
patients with LGG included data on molecular subtype. 
A median PFS and OS of 58.8 and 116.4 months were 
reported for 1p/19q codeleted patients, respectively [26]. 
In terms of IDH1, median PFS and OS were 134.4 and 
43.2 months for patients with mutant IDH1, respectively, 
and 21.6 and 7.2 months for patients with wild-type IDH1, 
respectively [26].
Adverse events for patients with LGG treated 
with TMZ
TMZ chemotherapy was also accompanied by 
adverse effects in all six studies included for analysis. 
Table 1: Treatment of low-grade glioma using PCV
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All PCV with RT 89.0


















Lebrun et al., 2007 [10] 33
PCV 19.0 75.0
Stege et al., 2005 [11] 21
All PCV 24.0 >













Abbreviations: OS – Overall Survival, PFS – Progression-Free Survival, RT – Radiation Therapy, PCV – procarbazine, 
CCNU (lomustine), and vincristine, Mt – Mutant, Wt- Wildtype.
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Table 2: Treatment of low-grade glioma using TMZ





























Fisher et al., 2015 [15] 129
All TMZ with RT 54.0 57.1
Hoang-Xuan et al., 2004 [16] 59
All TMZ
Kaloshi et al., 2007 [17] 149
All TMZ 28.0
Kesari et al., 2009 [18] 44
All









Koekkoek et al., 2016 [19] 53
All TMZ 39.1 20.0
Kouwenhoven et al., 2006 [20] 54
All TMZ* 81.0
Levin et al., 2006 [21] 28
All TMZ 31.0
Pace et al., 2003 [22] 43
All TMZ* 10.0




























Tosoni et al., 2008 [25] 30
All TMZ 21.8





























Abbreviations: OS – Overall Survival, PFS – Progression-Free Survival, A - Astrocytoma, OA – Oligoastrocytoma, OD – Oligodendroglioma, 
RT – Radiation Therapy, TMZ – Temozolomide, Mt – Mutant, Wt- Wildtype.
*TMZ administered after progression with either prior chemotherapy or radiation therapy.
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Of 234 patients, Baumert and colleagues reported that 
34 (15%) had at least one dose reduction, which was 
due to hematological toxicity in 19 patients (8%), non-
hematological toxicity in nine patients (4%), and for 
other reasons in 11 (5%) patients. Overall, grade 3–4 
haematological toxicity was recorded in 22 (9%) of 
235 patients in the safety population who received 
temozolomide, compared with one (<1%) of 228 patients 
in the safety population in the radiotherapy group. Kaloshi 
and colleagues reported that patients treated with TMZ 
chemotherapy tolerated it well, with 7% grade III and 
8% grade IV myelosuppression. Toxicities encountered 
in all studies included myelosuppression (including 
leukopenia, neutropenia and thrombocytopenia) and 
gastrointestinal complaints (mild nausea, emesis, and 
constipation).
DISCUSSION
Treatment of patients with LGG is directed toward 
improving the time to malignant transformation and overall 
survival, while limiting treatment-associated morbidities 
and neurologic disability. Objectives for surgery in this 
patient population include obtaining tissue for diagnosis, 
improving the quality of life through relief of focal 
deficits or improved seizure control, and cytoreduction. 
In a prospective study of patients with LGG with surgeon-
determined gross total resection, the presence of residual 
disease on post-operative imaging, astrocytic histology, 
and preoperative tumor size were prognostic factors for 
PFS [13]. In a retrospective population-based parallel 
cohort study, early surgery afforded a survival benefit 
compared to biopsy and watchful waiting in patients with 
low-grade glioma [27].
Figure 1: Overall and progression-free survival in patients with low-grade glioma. Kaplan-Meier curve showing superimposed 
studies that assessed (A) overall and (B) progression-free survival of patients with low-grade glioma.
Figure 2: Overall and progression-free survival based on 1p/19q status. Kaplan-Meier curve showing superimposed studies 
that assessed (A) overall and (B) progression-free survival of their patients with low-grade glioma based on 1p/19q status. “Intact” and 
“codel” refer to intact and co-deleted chromosome 1p and 19q status.
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The utility of involved field radiation therapy is 
patients with LGG has been clarified by three independent 
prospective trials. In an intergroup phase III prospective 
randomized clinical trial of low- versus high-dose 
radiation therapy in adults with LGG conducted by the 
North Central Cancer Treatment Group (NCCTG), Eastern 
Cooperative Oncology Group (ECOG) and the Radiation 
Therapy Oncology Group (RTOG), no survival difference 
was found between patients treated with 54 Gy and 65 
Gy, with lower doses tending to be associated with less 
treatment-related toxicities [28]. Similarly, the EORTC 
found no difference in survival in patients treated with 
45 Gy or 59.4 Gy, again with less adverse treatment-
related affects in the former group [29]. The EORTC 
22845 randomised trial found that early versus delayed 
RT confered a significant advantage in PFS, but confered 
no benefit in OS [30]. These findings led many clinicians 
to reserve radiotherapy for disease progression.
Previous studies from NCIC, the Temodal 
Brain Tumor Group, and EORTC, have shown a 
benefit to patients harboring a recurrent anaplastic 
oligodendroglioma and astrocytoma with both PCV 
and TMZ [24, 31–34]. The benefit of chemotherapy in 
this patient group was found to be more frequent and 
durable responses in patients with histologically classified 
oligodendroglioma, particularly in those with combined 
1p/19q loss, compared with those with an astrocytoma. 
Four trials investigated adjuvant chemotherapy in addition 
to radiotherapy. Three of these trials investigated PCV; 
histologic criteria were used to determine eligibility, with 
enrollment of patients with anaplastic oligodendroglioma 
in two of the trials [35, 36], and enrollment of patients 
with low-grade glioma in the other [9]. The fourth trial 
investigated concurrent and adjuvant TMZ in patients with 
anaplastic glioma with intact chromosomes 1p and 19q 
[37, 38]. All four trials found improvements in outcome 
with the addition of chemotherapy to radiotherapy [9, 
35, 36, 38]. Both the NCIC and EORTC trials found the 
addition of PCV chemotherapy to RT in patients with 
anaplastic 1p and 19q co-deleted tumors to result in 
improved benefit [39, 40]. These trials identified three 
candidate predictive markers for benefit from adjuvant 
PCV: IDH mutations, CpG island methylated phenotype, 
and MGMT promoter methylation [31, 32].
Monotherapy with PCV or TMZ chemotherapy 
or RT has been investigated by RTOG 0424 (PCV or 
TMZ versus RT for anaplastic glioma [15]) and EORTC 
22033-26033 and NOA-8 (TMZ versus RT in LGG with 
at least one high-risk feature [13, 41]). Both trials failed 
to show improvement in outcome after initial treatment 
with chemotherapy alone, with the suggestion as well 
of decreased survival after initial chemotherapy in some 
patient subgroups). In the absence of the results of a trial 
that formally compares chemotherapy alone to combined 
chemotherapy and RT, it is likely most reasonable to 
conclude that combination therapy improves survival 
compared with single modality treatment.
Recent molecular studies have shown that IDH 
wild-type low-grade glioma more closely approximates 
an early stage of primary glioblastoma than an IDH-
mutant LGG, and harbours a particularly unfavourable 
natural history [4]. These findings could be considered 
as biological support for the recommendation that these 
patients be treated with adjuvant temozolomide, as has 
been articulated by the CATNON authors. Conversely, the 
data predict that patients harbouring an IDH mutant LGG 
with codeletion of chromosomes 1p and 19q are likely 
to derive the greatest benefit from adjuvant therapy with 
Figure 3: Overall and progression-free survival based on IDH1 status. Kaplan-Meier curve showing superimposed studies that 
assessed (A) overall and (B) progression-free survival of their patients with low-grade glioma based on IDH1 status. “Wt” and “Mut” refer 
to wild-type and mutated IDH1.
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PCV. These data offer compelling reason to recommend 
treatment with radiation followed by adjuvant PCV in 
patients with an IDH mutant, 1p19q-codeleted tumour. 
That being said, there is not enough evidence to say RT 
and TMZ are an inferior option, as this is primarily due to 
lack of trials investigating this subject matter.
There is the further concern that TMZ chemotherapy 
may direct these tumors toward a hypermutator phenotype 
at the time of progression [42]. It is unclear if the same risk 
exists with PCV therapy. More critically, these findings 
were identified through study of a small cohort of patients, 
and need to be validated in a larger treatment group.
As patients with LGG often experience long periods 
of disease stability, the effect of therapy on health-
related quality of life (HRQoL) is all the more critical. 
While the relatively lesser toxicity of TMZ compared to 
PCV has led many practitioners to prefer TMZ for their 
patients with low-grade glioma [43], a recent systematic 
review of patient-reported HRQoL bemoaned the paucity 
and heterogeneity of reporting of HRQoL in the LGG 
literature [44]. A longitudinal study of HRQoL in patients 
with LGG based on patient self-reporting found that 
patients with LGG had worse physical role functioning 
and general health perceptions at long-term follow-up (on 
average, twelve years following diagnosis) than healthy 
matched controls, independent of treatment type [45]. 
No significant differences in HRQoL or global cognitive 
functioning were seen in patients with high-risk LGG 
randomized to treatment with TMZ or radiation in EORTC 
22033-26033 [46]. While Pace and colleagues performed 
QoL testing on patients receiving salvage chemotherapy 
with PCV or TMZ for radiographic progression of LGG, 
their analysis did not allow for comparison of results from 
patients in these two subgroups [22]. We were unable 
to find any other studies in the literature reporting QoL 
measures on patients with LGG who were treated with 
PCV.
It is valuable to recollect that the only Level 1 
evidence for TMZ in LGG offered by the literature 
demonstrates the inferiority of TMZ monotherapy to 
radiation therapy in this patient cohort. Our understanding 
of the role of TMZ compared to PCV in the treatment of 
patients with lower-grade glioma will be informed by the 
CODEL (ALLIANCE-N0577-CODEL) trial, which has 
reopened as a two-arm comparison of radiation therapy 
with adjuvant PCV vs. radiation therapy with concurrent 
and adjuvant TMZ in patients with 1p/19q-codeleted 
anaplastic (Grade III) oligodendroglioma; whether these 
findings will be generalizable to patients with Grade II 
codeleted tumors is unclear. Similarly, in interim results 
from the CATNON trial (EORTC study 26053-22054), 
in which patients with newly diagnosed non-co-deleted 
anaplastic glioma were randomized to RT alone, RT 
with adjuvant TMZ, or RT with concurrent TMZ with 
or without adjuvant TMZ, adjuvant temozolomide 
chemotherapy was found to be associated with a 
significant survival benefit compared to RT alone. The 
data was not yet mature at the time of planned interim 
analysis to determine superiority between concurrent and 
adjuvant TMZ versus adjuvant TMZ alone. Unfortunately, 
IDH status was not reported with the interim analysis 
for the patient cohort enrolled in CATNON, but will be 
included in the final analysis. Their findings will likely 
represent results from a mixed population of IDH wild-
type and mutated patient; in fact, the quick separation 
of the survival curves for patients treated with RT alone 
versus RT with adjuvant TMZ (within one year of 
treatment), and the lower than expected number of tumors 
with MGMT promoter methylation (a finding typical for 
IDH-mutant LGG), suggest that many of these patients 
will be found to harbour IDH wild-type tumors.
Our study does not allow us to answer a number of 
critical real-time problems. For example, how should we 
advise the patient who has undergone gross total resection 
of an LGG that harbours histologic, molecular, or 
demographic features of a high-risk lesion? Some authors 
have advised that patients who have undergone GTR of 
an LGG (i.e. no residual FLAIR signal abnormality) may 
be followed expectantly (a “wait and see approach”) and 
treated if found to have radiographic recurrence [47]. 
It is unlikely that future trials will include a subgroup 
that is randomized to treatment with surgical resection 
alone to allow us the answer to this question. Similarly, 
the literature reporting on the use of adjuvant therapy 
in patients with LGG lacks granularity. Should PCV or 
TMZ be recommended as salvage therapy for a patient 
who has tumour recurrence following distant radiotherapy 
for a high-risk LGG without its histological progression? 
Should PCV or TMZ be used in a patient found to have 
an intermediate risk lower-grade glioma, for example, a 
Grade III IDH-mutated, 1p and 19q intact tumour? What 
patient presentation does a combination of RT and TMZ 
prove to be the more valuable option of treatment?
Finally, it it is worthwhile to note some of the 
critical limitations of the data included in our review. For 
example, these studies all predate the recognition of the 
intermediate risk LGG represented by tumors harboring 
an IDH mutation, but lacking 1p and 19q codeletion, and 
harboring instead deletion of ATRX. In Figure 2, patients 
captured within the 1p19q-intact cohort may include both 
this intermediate subgroup and higher-risk patients with 
IDH wild-type tumors. Conversely, in Figure 3, patients 
included within the IDH mutant subgroup may include 
patients with both lower-risk IDH mutant, 1p and 19q co-
deleted tumours, as well as patients with intermediate IDH 
mutant, 1p and 19 intact, ATRX-deleted tumors.
For now, the data suggest that for patients harboring 
a tumor with an unfavorable natural history, such as those 
with intact 1p/19q and wild-type IDH1, TMZ and RT 
may be the best option. Conversely, the data suggest that 
patients with biologically favorable LGG are likely to 
derive the most significant benefit from RT and adjuvant 
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PCV. A prospective trial directly comparing PCV and TMZ 
in patients with high-risk low-grade glioma is needed.
MATERIALS AND METHODS
This systematic review was conducted according to 
PRISMA guidelines (Supplementary Figure 2) [7]. The 
primary literature search was conducted via PubMed for 
articles published between January 1, 1995 and May 1, 
2017, using the search terms, “Low-grade glioma AND 
temozolomide OR TMZ”, “Low-grade glioma AND PCV 
OR procarbazine/lomustine/vincristine”, and “Low-grade 
glioma AND chemotherapy”. References from relevant 
articles were searched. Level I, II, and III studies were 
included if published in English, consisted of patients 16 
years of age and older, noted LGG subtype, progression-
free survival (PFS) and overall survival (OS) as primary 
or secondary end points, and treatment course. Exclusion 
criteria included pediatric patient populations and lack 
of differentiation of survival data based on treatment 
or glioma-subtype. Data including study design, 
patient population demographics, histology, molecular 
subtype, PFS, OS, and treatment regimens and durations 
were extracted. Levels of evidence were categorized 
as follows: level I (properly powered and conducted 
randomized-control trial), level II (well-designed 
controlled trial without randomization; prospective 
comparative cohort trial), and level III (retrospective 
cohort study) [48]. Figures including superimposed 
Kaplan-Meier curves were generated using Digitizelt 
(Bormisoft, Braunschweig, Germany, http://www.
digitizeit.de), a software designed to digitize scanned 
graphs and charts into (x,y)-data. Software errors in data 
recognition were manually edited by the authors (K.H. 
and S.D.).
CONCLUSIONS
In patients harboring a tumor with an unfavorable 
natural history, such as those with intact 1p/19q and wild-
type IDH1, RT/TMZ plus adjuvant TMZ may be the best 
option. Conversely, patients with biologically favorable 
high-risk LGG are likely to derive the most benefit from 
RT and adjuvant PCV. While unlikely due to the resources 
and time required, a prospective trial directly comparing 
PCV and TMZ in patients with high-risk low-grade glioma 
is needed.
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Highlights
•	 Low-grade gliomas encompass a clinically and 
biologically heterogeneous group of tumors.
•	 Adjuvant therapy with PCV results in prolonged PFS 
and OS in patients with newly diagnosed high-risk 
LGG.
•	 Adjuvant therapy with temozolomide is associated with 
lower toxicity than therapy with PCV.
•	 Patients with biologically favorable high-risk LGG are 
likely to derive the most benefit from RT and adjuvant 
PCV.
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